

Accepted Manuscript

A Jagged1-Notch4 Molecular Switch Mediates Airway Inflammation by Ultrafine Particles

Mingcan Xia, PhD, Hani Harb, PhD, Arian Saffari, PhD, Constantinos Sioutas, Sc.D.,
Talal A. Chatila, MD, MSc



PII: S0091-6749(18)30510-4

DOI: [10.1016/j.jaci.2018.03.009](https://doi.org/10.1016/j.jaci.2018.03.009)

Reference: YMAI 13369

To appear in: *Journal of Allergy and Clinical Immunology*


Received Date: 16 July 2017

Revised Date: 14 March 2018

Accepted Date: 23 March 2018

Please cite this article as: Xia M, Harb H, Saffari A, Sioutas C, Chatila TA, A Jagged1-Notch4 Molecular Switch Mediates Airway Inflammation by Ultrafine Particles, *Journal of Allergy and Clinical Immunology* (2018), doi: 10.1016/j.jaci.2018.03.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Xia, Harb et al JACI (2018)

**A Jagged1-Notch4 Molecular Switch Mediates Airway Inflammation by Ultrafine
Particles**

Mingcan Xia, PhD^a, Hani Harb, PhD^a, Arian Saffari, PhD^b, Constantinos Sioutas, Sc.D.^b
and Talal A. Chatila, MD, MSc^a

^aDivision of Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard
Medical School, Boston, MA 02115; ^bDepartment of Civil and Environmental
Engineering, University of Southern California, Los Angeles, California, 90089.

Supported by National Institutes of Health grant 2R01AI065617 (to T.A.C.).

Corresponding Author: Corresponding author: Talal A. Chatila, MD, MSc, Division of
Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical
School, Boston, MA 02115. Phone: 617-919-3529 Fax: 617-730-0528. E-mail:
talal.chatila@childrens.harvard.edu.

ABSTRACT

Background: Exposure to traffic-related particulate matter (PM) promotes asthma and allergic diseases. However, the precise cellular and molecular mechanisms by which PM exposure acts to mediate these effects remain unclear.

Objective: We sought to elucidate the cellular targets and signaling pathways critical for the augmentation of allergic airway inflammation induced by ambient ultra fine particles (UFP).

Methods: We employed *in vitro* cell culture assays using lung-derived antigen presenting cells and allergen-specific T cells, and *in vivo* mouse models of allergic airway inflammation that employed myeloid lineage-specific gene deletions, cellular reconstitution approaches and antibody inhibition studies.

Results: We identified lung alveolar macrophage (AM) as the key cellular target of UFP in promoting airway inflammation. Aryl hydrocarbon receptor (AhR)-dependent induction of Jagged 1 (Jag1) expression in AM was necessary and sufficient for the augmentation of allergic airway inflammation by UFP. UFP promoted Th2 and Th17 cell differentiation of allergen-specific T cells in a Jag1- and Notch4-dependent manner. Treatment of mice with an anti-Notch 4 antibody abrogated the exacerbation of allergic airway inflammation induced by UFP.

Conclusion: UFP exacerbate allergic airway inflammation by promoting a Jag1-Notch4-dependent interaction between Alveolar Macrophages and Allergen-Specific T cells, leading to augmented Th cell differentiation.

Key messages:

- Lung alveolar macrophages (AM) are a key target of traffic related particulate matter (PM) in promoting allergic airway inflammation.
- Traffic-related ultra fine particles (UFP) induce the expression of the Notch ligand Jagged 1 (Jag1) on AMs via aryl hydrocarbon receptor
- Jag1 on AM interacts with Notch4 on naïve allergen-specific T cells to promote Th2 and Th17 cell differentiation
- Treatment with an anti-Notch 4 mAb abrogates the exacerbation of allergic airway inflammation induced by UFP.

Capsule summary

Traffic related particulate matter induce the expression of Jagged1 on alveolar macrophages in an aryl hydrocarbon receptor-dependent manner, which in turn interacts with Notch4 on Allergen-Specific T cells to promote allergic airway inflammation.

Key words: Airway hyper-responsiveness; Allergic Airway Inflammation; Alveolar macrophages; Aryl Hydrocarbon Receptor; Asthma; Jagged1; Notch; Notch4, Traffic-Related Particulate Matter; Ultra-Fine Particles.

Abbreviations. Antibodies: Ab; AhR: Aryl hydrocarbon receptor; APC: Antigen presenting cells; BAL: Bronchoalveolar lavage; FACS: Fluorescein-activated cell sorting; FP: Fine particles; Jag1: Jagged 1; RL: Lung resistance; PM: Particulate matter; UFP: Ultrafine particles; YG: Yellow green.

INTRODUCTION

It is well appreciated that exposure to air pollution, especially particulate matter (PM) emitted by combustion sources, play an important role in the increased incidence and prevalence of asthma in recent decades¹⁻⁶. Among air pollutants, exposure to PM shows the strongest correlation with adverse respiratory health effects⁷⁻¹⁰. These particles have been shown to promote Th2 and Th17 cell responses and upregulate IgE production in the exposed host¹¹⁻¹⁵.

Inhaled PM exhibit differential airway penetrance that stratifies according to size. Unlike coarse particles (CP; ≥ 2.5 μm in diameter) trapped in the nasopharyngeal region, fine particles (FP; ≤ 2.5 μm in diameter) and ultra-fine particles (UFP; ≤ 0.2 μm in diameter) are able to penetrate into the lower respiratory tract where they are taken up by antigen-presenting cells (APC) to mediate local and systemic inflammation¹⁶. PM modulation of APC function maybe particularly relevant to the adjuvant-like effect of PM in promoting immune responses to allergens^{13, 17}. Our recent studies have identified a key mechanism common to both UFP and FP by which they augment allergic responses, involving their induction of the Notch receptor ligand Jagged1 (Jag1) on APC¹⁵. This induction is mediated by the activation by PM-associated polycyclic aromatic hydrocarbons (PAH) of the aryl hydrocarbon receptor (AhR), which in turn mediates the transcriptional activation of *Jag1*. Jag1 engages Notch receptors on allergen-specific T cells, leading to their augmented differentiation into disease-promoting Th cells. These studies did not precisely identify the relevant APC species involved in this process, nor the target Notch receptor(s) mediating the response to PM-induced Jag1.

Lung macrophages have previously been implicated in the uptake of and response to PM¹⁸⁻²⁰. They include two major subsets: alveolar macrophages (AM), expressing high levels of the β 2 integrin CD11c (CD11c^{hi}) and interstitial macrophages (IM) expressing intermediate levels of CD11c (CD11c^{int})^{21, 22}. Studies have shown that both populations promote immune tolerance in the steady state by inducing naive T cell to Treg cell differentiation^{23, 24}. However, inflammatory stimuli, including allergens and endotoxin, modulate the expression of co-stimulation molecules and alter the potency of lung macrophage as antigen presenting cells^{25, 26}. In a similar vein, exposure of AM to PM alters their function, rendering them pro-inflammatory²⁷. In addition to targeting lung macrophages, PM have been shown to potentiate the antigen presenting function of lung dendritic cells (DC)²⁸. The relative contribution of the respective APC type to the allergic airway inflammatory response induced by PM remains to be fully elucidated.

To investigate mechanisms by which PM exposure may target lung APC to promote allergic diseases, we employed a range of genetic, immunological and whole animal approaches. Here, we provide evidence for a critical role for PM-mediated, AhR-dependent Jag1 induction in AM in promoting allergic airway inflammation by a process involving Notch4-dependent allergen-specific T helper cell differentiation.

METHODS

Mice. *Il4ra*^{R576} and *Foxp3*^{EGFP} mice were previously described^{15, 29, 30}. The following mice were obtained from the Jax Lab: BLAB/c (WT), *Ahr*^{fl/fl} (*Ahr*^{tm3.1Bra})³¹, *Lyz2*^{Cre} (CreB6.129P2-*Lyz2*^{tm1(cre)lfo}/J) and *CD11c*^{Cre} (B6.Cg-Tg(*Itgax-cre*)1-1Reiz/J)³². *DO11.10Rag2*^{-/-} mice were obtained from Taconic farms. They were crossed with *Il4ra*^{R576} mice to generate *DO11.10Rag2*^{-/-}*Il4ra*^{R576}*Foxp3*^{EGFP} mice³⁰. *Jag1*^{fl/fl} mice were kindly provided by Dr. Freddy Radtke³³.

Particles. UFP (≤0.18 μm) were collected in an urban area of downtown Los Angeles, as previously reported¹⁵. Constituent components of the particles were analyzed as described and are summarized in **Table E1** in the Online Repository³⁴. The respective particles were suspended in an aqueous solution, with the hydrophilic components becoming part of the solution, while the solid non-soluble UFP cores are left in suspension. The entire mixture was administered intranasally, as indicated below

T cell co-cultures with lung macrophages and DC. Naïve CD4⁺DO11.10⁺ T cells were isolated from spleens of CD4⁺DO11.10⁺RAG2^{-/-} *Il4ra*^{R576}*Foxp3*^{EGFP} mice by fluorescein-activated cell sorting (FACS). AM and IM were isolated by FACS and were aliquoted at 2x10⁴ cells in 48 well plates, then either sham treated or treated overnight with UFP at 10 μg/ml. The UFP treatment did not induce increased apoptosis as compared to sham treatment, as assessed by Annexin V staining (data not shown). The APC were washed twice with PBS to remove residual UFP, and the T cells were then added at 4x10⁵ cells/well in a final volume of 0.5 ml 10% fetal calf serum/RPMI culture

medium. Cultures were treated with the OVA₃₂₃₋₃₃₉ peptide at 1μM, as indicated. Anti-murine Notch Ab were added at 10 μg/ml each, as indicated.

Allergic sensitization and challenge. Mice were sensitized to OVA by intraperitoneal (*i.p.*) injection of 100 μg OVA in 100 μl PBS, then boosted two weeks later with a second *i.p.* injection of OVA in PBS. Control mice were sham sensitized and boosted with PBS alone. Starting on day 29, both OVA and sham-sensitized mice were challenged with aerosolized OVA at 1%, for 30 minutes daily for 3 days. Two hours before each OVA aerosol exposure, subgroups of mice were given intranasally (*i.n.*) either PBS or UFP at 10 μg/100μl PBS/instillation. For anti-Notch4 antibody blocking, 150 μg Armenian hamster anti-mouse Notch4 IgG mAb (clone HMN4-14; Bio X Cell)³⁵, or control Armenian hamster IgG polyclonal antibodies (Ab) (Bio X cell), were suspended in 100 μl PBS buffer and administered daily for three consecutive days during OVA aerosol challenge. Mice were euthanized on day 32 post sensitization and analyzed. For dust mite-induced allergic airway inflammation, mice received 5μg of lyophilized *D. Pteronyssinus* extract (Greer) in 100 μl PBS intranasally for 3 days at the start of the protocol then challenged with the same dose of *D. Pteronyssinus* extract on days 15-17 with or without UFP. Mice were euthanized on day 18 and analyzed for measures of airway inflammation. Bronchoalveolar lavage (BAL) fluid and lung tissues were obtained and analyzed for cellular components and T cell cytokine expression following previously published methods^{15, 30}.

For AM, IM and DC cell transfer studies, cells were isolated from either *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} donor mice by FACS. The cells were cultured overnight and either sham treated, or loaded with OVA₃₂₃₋₃₃₉ peptide at 5 nM peptide concentration

either alone or together with UFP at 10 µg/ml. The cells were transferred intratracheally to OVA-sensitized *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} recipient mice at 10⁵ cells/mouse repeated twice over two days. The mice were euthanized on the third day and analyzed for the different parameters of allergic airway inflammation.

Lung histopathology staining. Paraffin-embedded lung sections were stained with hematoxylin and eosin (H&E) as described³⁶. The lung pathology was scored by blinded operators. Inflammation was scored separately for cellular infiltration around blood vessels and airways: 0, no infiltrates; 1, few inflammatory cells; 2, a ring of inflammatory cells 1 cell layer deep; 3, a ring of inflammatory cells 2–4 cells deep; 4, a ring of inflammatory cells of >4 cells deep³⁷. A composite score was determined by the adding the inflammatory scores for both vessels and airways. The number and distribution of goblet cells was assessed by Periodic Acid Schiff (PAS) staining of mucin granules. Individual airways (bronchi/bronchioles) were scored for goblet cell hyperplasia according to the following scale: 0, no PAS-positive cells; 1, <5% PAS-positive cells; 2, 5 to 10% PAS-positive cells; 3, 10 to 25% PAS-positive cells; and 4, > 25% PAS-positive cells³⁸.

Statistical analysis. Student's two-tailed *t*-test, one and two way ANOVA and repeat measures two way ANOVA with Bonferroni post-test analysis of groups were used to compare test groups, as indicated. A *p* value <0.05 was considered statistically significant.

Study approval. All animal studies were reviewed and approved by the Boston Children's Hospital office of Animal Care Resources.

Other Methods. Information real time PCR analysis, flow cytometry (including Fluoresbrite® yellow green (YG) microspheres and nanobeads), intracellular staining reagents, Ab and methods, IgE ELISA and measurement of airway hyper-responsiveness are provided in the Methods section in this article's Online Repository at www.jacionline.org.

RESULTS

Lung Macrophages are the major cellular target of UFP in the lungs under basal and inflammatory conditions. To further elucidate the role of the Jag1-AhR-Notch pathway in the promotion of airway inflammation by UFP, we first sought to establish detailed immunophenotypic characterization of the APC targeted by PM in our study model, both under basal and especially allergic inflammatory conditions. We focused in our studies on UFP, which are particularly toxic by virtue of their deep penetrance, large surface area to size ratios, higher content per mass of PAH and greater capacity to induce oxidative stress^{39, 40}. We employed an OVA-induced allergic airway inflammation model using the *Il4ra*^{R576} mice. These mice carry an IL-4 receptor alpha chain (IL-4R α -R576) variant that mediates exaggerated allergic airway inflammation to allergen, alone or in combination with UFP, by virtue of mediating IL-4R-dependent mixed Th2/Th17 cell inflammation^{15, 30}. Mice were sensitized by intra-peritoneal injection of OVA and then challenged by repeated inhalation of PBS (sham challenge) or 1% aerosolized OVA. Subgroups of mice were treated intra-nasally with UFP in combination with Fluoresbrite® YG nanobeads (0.05 μ m effective diameter) or microspheres (1 μ m effective diameter) 2hr before the OVA aerosol challenge⁴¹. Nanobead fluorescence positive cell populations were analyzed by flow cytometry (**Fig 1, A and B**). In the absence of inflammation (PBS-sensitized, OVA-treated group), $\geq 95\%$ nanobead-uptaking cells were CD45⁺F4/80⁺CD64⁺MHCII⁺CD11b^{Int}CD11c^{Hi} alveolar macrophage whereas CD45⁺F4/80⁺CD64⁺MHCII⁺CD11b^{Hi}CD11c^{Int} interstitial macrophage represented 2-3% of total microsphere positive cells (**Fig E1-E3** in the

Online Repository)⁴². In the context of allergic airway inflammation induced by OVA and especially by OVA+UFP, about 85% of nanobeads-uptaking cells were macrophages, distributed at a 70:30 ratio between AM and IM (**Fig 1 A -C**). The particle-uptaking AM population was CD38^{Int}Egr2^{Hi} (M2-like), while the IM population was CD38^{Hi}Egr2^{Int} (M1-like) (**Fig E3, A and B** in the Online Repository)⁴³. In agreement with their M2-like phenotype, *in vitro* treatment of cell-sorted AM with UFP sharply upregulated their production of the cytokines IL-10, CCL17, IL-6 and TNF- α but induced little change in their baseline production of IL-12 (**Fig E3, C**)^{44, 45}. Of the remaining beads (15%), about 2/3rd were picked up by CD11c^{hi}CD11b^{int}CD8 α ⁺CD103⁺B220⁻PDCA1⁻ classical (c)DCs⁴⁶, and the rest by Gr1⁺SiglecF^{low} neutrophils (**Fig 1, B and C, and Fig. E1** in the Online Repository). These results indicated that alveolar and interstitial macrophage were the major cell subset responsible for the clearance of inhaled UFP in the context of allergic airway inflammation. Similar cellular localization results were obtained when Fluoresbrite® YG microsphere beads were used instead of nanobeads, consistent with our previously published data showing FP and UFP sharing the same AhR-Notch-Jag1 mechanism of action in promoting allergic airway inflammation (**Fig. E4** in the Online Repository).

UFP differentially induce Jag1 expression in lung AM. UFP induces Jag1 expression in an AhR-dependent manner in bone marrow-derived dendritic cells¹⁵ and in macrophages (**Fig E5, A** in the Online Repository). We examined the expression of *Jag1* transcripts in different APC populations isolated from the lungs of *Il4ra*^{R576} mice and either sham treated or treated *in vitro* with UFP. Jag1 expression was highest at baseline in AM as compared to IM and DC (**Fig 1, D**). *In vitro* treatment with UFP super-

induced *Jag1* transcript expression in AM, whereas the same treatment was associated with modest increases in IM and DC (**Fig 1, D**). In contrast, treatment with Fluoresbrite® YG nanobeads failed to induce *Jag1* expression on AM (**Fig E2, A**). It also failed to affect airway inflammation induced by OVA despite the Fluoresbrite® YG nanobeads localizing to AM when administered intranasally (**Fig E2, B- D**). Deletion of a floxed *Ahr* allele by means of a Cre recombinase driven by the lysozyme 2 gene promoter (*Lyz2^{Cre}*), which is active in myeloid-lineage cells, greatly reduced baseline expression of *Jag1* transcripts in AM of *Il4ra^{R576}Lyz2^{Cre}Ahr^{ΔΔ}* mice and abolished its super-induction by UFP. While a similar trend was also noted in the other cell types, there was partial sparing of *Jag1* expression in DC. Flow cytometric analysis confirmed the heightened expression of *Jag1* in AM as compared to the other cell types and its downregulation upon *Ahr* deletion (**Fig 1, E**). UFP-induced *Jag1* expression in bone marrow-derived macrophages was similarly affected by *Lyz2^{Cre}*-driven *Ahr* deletion (**Fig E5** in the Online Repository). Furthermore, sensitization of mice with OVA followed by challenge with OVA and UFP resulted in the preferential induction of *Jag1* on AM as compared to IM and DC, and this induction was reversed upon by *Lyz2^{Cre}*-driven *Ahr* deletion (**Fig E5, B**).

These results were further ascertained by the deletion of a floxed *Jag1* gene in myeloid lineages using *Lyz2^{Cre} (Il4ra^{R576}Lyz2^{Cre}Jag1^{ΔΔ})* (**Fig 1, F and G**). *Jag1* transcript expression and *Jag1* surface staining were completely abrogated in AM both at baseline and following UFP treatment. Reduced *Jag1* transcript expression and *Jag1* protein staining persisted in IM, while their levels were unaffected in DC. These findings confirmed AM as the principal APC cell type expressing *Jag1* both at baseline and

following UFP treatment and that this expression proceeds by an *Ahr*-dependent mechanism. They also showed that *Lyz2^{Cre}* preferentially targets *Jag1* in macrophages, particularly AM, while largely sparing it in DC, consistent with previous lineage tracing analysis on the activity of *Lyz2^{Cre}* in macrophages versus dendritic cells ⁴⁷.

UFP-treated AM promote Th cell differentiation in a Jag1-dependent mechanism.

To examine if induction of *Jag1* expression in AM by UFP augments allergen-induced Th cell differentiation, we employed an *in vitro* Th cell differentiation system involving naïve *Il4ra^{R576}*DO11.10⁺CD4⁺ T cells, derived from *DO11.10⁺Rag2^{-/-}* mice. Naïve DO11.10⁺CD4⁺ T cells were incubated with FACS-purified AM isolated from *Il4R⁵⁷⁶* or *Il4ra^{R576}Lyz2^{Cre}Jag1^{Δ/Δ}* mice. The AM were either sham pulsed with PBS or pulsed with the OVA peptide OVA₃₂₃₋₃₃₉, alone or together with UFP. At the end of the incubation period, Th cell cytokine expression was analyzed in gated CD4⁺Foxp3⁻ (non-regulatory) T cells. Co-culture with OVA₃₂₃₋₃₃₉ peptide-pulsed *IL4R^{R576}* AM resulted in increased production by DO11.10⁺CD4⁺Foxp3⁻ T cells of IL-17, IL-13 and IL-4, and to much lesser extent IFN-γ, as revealed by flow cytometric staining (**Fig E6** in the Online Repository and **Fig 2**). Expression of the first three cytokines was markedly upregulated by the addition of UFP (10 μg/ml), whereas that of IFN-γ was down-regulated, consistent with exaggerated Th2/Th17 skewing ³⁰. In contrast, the induction of IL-17, IL-13 and IL-4 expression in DO11.10⁺CD4⁺ T cells by OVA₃₂₃₋₃₃₉ was moderately inhibited, and their super-induction by UFP completely abolished, when *Il4ra^{R576}Lyz2^{Cre}Jag1^{Δ/Δ}* AM were used as APC. IFN-γ expression in those co-cultures was also profoundly impaired (**Fig 2, A and B**).

We also employed the DO11.10 cell *in vitro* Th cell differentiation system to examine the impact of UFP treatment on the capacity of AM to support the differentiation of naïve allergen-specific T cells into induced Treg cells. In the absence of UFP, OVA₃₂₃₋₃₃₉-loaded AM drove the differentiation of up to 40% of naïve *Il4ra*^{R576}DO11.10⁺CD4⁺ T cells into Foxp3⁺ induced T regulatory (iTreg) cells. Treatment with UFP partially inhibited iTreg cell differentiation independent of Jag1 expression (**Fig 3, A and B**). Critically however, UFP treatment of OVA₃₂₃₋₃₃₉ peptide-presenting AM skewed the formed iTreg cells into secreting Th2/17 cell cytokines, including IL-4, IL-13 and IL-17, but not the Th1 cytokine IFN- γ . This skewing was largely reversed by deletion of *Jag1* in AM (**Fig 3, C and D**). These results indicated that UFP adversely affected allergen-specific iTreg cell differentiation, in part by destabilizing newly formed iTreg cells towards Th2/17 cell differentiation in a Jag1-dependent manner.

Jag1 deletion in myeloid lineages abolishes the augmentation of allergic airway inflammation by UFP. To determine the role of Jag1 expression on AM in supporting UFP upregulation of allergic airway inflammation *in vivo*, we first employed *Lyz2*^{Cre} to delete component genes of the *Ahr-Jag1* genetic circuit in myeloid lineage cells. Accordingly, *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1* ^{Δ/Δ} mice and *Il4ra*^{R576} mice were sensitized by intraperitoneal injection of OVA and then challenged by inhalation of 1% aerosolized OVA. Control mice were sham sensitized with PBS and challenged with aerosolized OVA. Subgroups of mice were treated intra-nasally with UFP (10 μ g/institution) or PBS 2 hr before the OVA aerosol challenge⁴¹. Sensitization and challenge of *Il4ra*^{R576} mice with OVA resulted in a robust airway inflammatory response, characterized by airway inflammation and hyper-responsiveness, eosinophilia and T cell infiltration in the BAL

fluid, elevated total and OVA-specific serum IgE responses, and augmented Th2 and Th17 cell responses (**Fig. 4A-K**). All these parameters were markedly augmented by UFP exposure during the OVA challenge phase. OVA sensitization and challenge of *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice also resulted in a robust allergic airway inflammatory response that was similar to that noted in OVA sensitized and challenged *Il4ra*^{R576} mice. However, the augmentation by UFP of all the aforementioned parameters of allergic airway inflammation was completely abrogated in *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice, indicating a requisite requirement for Jag1 expression in myeloid lineages for UFP to exert its pro-inflammatory effects in the airways (**Fig. 4A-I**).

We also examined the role of Jag1 expression in myeloid lineage cells to mediate the augmentation by UFP of allergic airway inflammation induced upon the intranasal treatment of *Il4ra*^{R576} mice with extracts of house mites (*D. pteronyssinus*), a common and potent human allergen. Results were concordant with those observed with OVA sensitization and challenge. Whereas UFP augmented the airway inflammation induced by treatment of *Il4ra*^{R576} mice with a low dose of *D. pteronyssinus* (5 μg), this effect was abrogated in *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice (**Fig. E7** in the Online Repository). Myeloid lineage-specific deletion of *Ahr* in *Il4ra*^{R576} mice (*Il4ra*^{R576}*Lyz2*^{Cre}*Ahr*^{Δ/Δ}) also abrogated the capacity of UFP to augment the various parameters of allergic airway inflammation induced by OVA, consistent with the requirement for AhR signaling for the induction of Jag1 expression by UFP (**Fig E8** in the Online Repository). In contrast, deletion of *Jag1* in all CD11c⁺ APC lineages using a *CD11c*^{Cre} did not inhibit the promotion of airway inflammation by UFP and in fact worsened it, indicating a unique and specific

requirement for Jag1 induction by UFP in AM for their acquisition of a pro-inflammatory function (**Fig E9** in the Online Repository).

Jag1 expression in AM is sufficient to mediate UFP upregulation of allergic airway inflammation. To specifically establish the role of Jag1 expression in AM in the exacerbation of allergen-induced airway inflammation by UFP, we examined the capacity of AM to rescue the UFP effect when transferred into *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice. Accordingly, AM were isolated from either *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice, either sham treated or loaded with OVA₃₂₃₋₃₃₉ peptide in the absence or presence of UFP. The cells were transferred into the airways of *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice that were sensitized with OVA, which were then examined for induction of allergic airway inflammation. Results revealed that transfer of Jag1-sufficient OVA₃₂₃₋₃₃₉ peptide-pulsed and UFP-treated *Il4ra*^{R576} AM into OVA-sensitized *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice recapitulated all the stigmata of exacerbated allergic airway inflammation induced by UFP, including augmented tissue inflammation, increased airway hyper-responsiveness, serum total and OVA-specific IgE, and BAL fluid CD4⁺ T cell infiltration and eosinophilia (**Fig 5, A-G**). It also augmented Th cell cytokine production and Treg cell destabilization into Th cell like phenotypes (**Fig 5, H-O**). In contrast, transfer of similarly treated Jag1-deficient *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} AM failed to do so, indicating that Jag1 expression of AM is sufficient to restore the capacity of UFP to augment allergen-induced airway inflammation.

We also examined the capacity of IM and DC isolated from the lungs of *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice and sham treated or loaded with OVA₃₂₃₋₃₃₉ or OVA₃₂₃₋₃₃₉ + UFP to promote airway inflammation when transferred intra-tracheally into OVA-

sensitized *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice. However, unlike the case of Jag1-sufficient AM, transferred IM failed to promote allergic airway inflammation irrespective of their treatment modality (**Fig E10, A-F** in the Online Repository). The transferred DC also failed to induced airway hyper-responsiveness. OVA₃₂₃₋₃₃₉-loaded DC induced suboptimal tissue infiltration with eosinophils and Th cells as compared to AM, which was not augmented by UFP treatment. These results are consistent with the unique role of Jag1-sufficient AM in promoting airway inflammation and in its super-induction by UFP (**Fig E10, G-L** in the Online Repository).

Promotion by UFP of allergen-induced Th cell differentiation involves Jag1-Notch4 interaction. We next determined the role of the respective Notch receptors in mediating the pro-inflammatory effects of Jag1 expressed by AM upon UFP treatment. Accordingly, we first analyzed the ex-vivo expression of the different Notch receptors in FACS-purified CD4⁺EGFP⁻ T conventional cells and CD4⁺EGFP⁺ Treg cells, isolated from *Il4ra*^{R576}*Foxp3*^{EGFP} mice. The cells were isolated from the spleens of unmanipulated mice and from the lungs of mice subjected to allergic airway inflammation without or with UFP co-treatment. Splenic CD4⁺ T cells primarily expressed Notch1 and Notch2 (data not shown), consistent with our previous results⁴⁸. In contrast, Notch4 expression was upregulated in CD4⁺ T cells isolated from the lungs of mice sensitized with OVA and challenged with OVA+UFP, to become the highest among the four Notch receptors (**Fig E11** in the Online Repository). Notch1 and Notch2 expression was also upregulated but to a lesser extent, while that of Notch3 decreased. Informed by the above results, we next employed the *in vitro* co-culture system described in **Fig 2** to determined the capacity of neutralizing Notch1, 2 and 4 Ab to

reverse the augmentation by UFP treatment of OVA₃₂₃₋₃₃₉ peptide-presenting AM of Th cell cytokine production by responding DO11.10 T cells. FACS-purified Jag1-sufficient (*Il4ra*^{R576}) or -deficient (*Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ}) AM were either sham treated or treated with OVA₃₂₃₋₃₃₉ peptide, either alone or together with UFP. They were co-cultured with naïve *Il4ra*^{R576} DO11.10⁺CD4⁺ T cells in the presence of either isotype control mAbs or neutralizing mAbs specific for individual Notch receptors, and the T cells were examined for Th cell cytokine expression. As expected, UFP treatment of OVA₃₂₃₋₃₃₉ peptide-pulsed *Il4ra*^{R576} AM upregulated the production by DO11.10⁺CD4⁺Foxp3⁻ T cells of IL-17, IL-13 and IL-4, and to much lesser extent IFN-γ, whereas this effect was abolished when *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} AM were used as APC. Critically, upregulation of Th cell cytokine expression by UFP, including IL-4, IL-13 and IL-17, was uniformly inhibited by co-treatment with a highly specific neutralizing anti-Notch4 mAb (**Fig 6 and Fig E12** in the Online Repository)⁴⁹. Anti-Notch4 mAb also inhibited the residual IFN-γ production induced by OVA, alone or with UFP. In contrast, treatment with neutralizing mAbs specific for other Notch receptors gave partial and/or selective inhibitory results (**Fig E12** in the Online Repository). Anti-Notch4 mAb also suppressed the production by DO11.10⁺CD4⁺Foxp3⁺ iTreg cells of Th cell cytokines when cultured with OVA₃₂₃₋₃₃₉ peptide-presenting AM that were treated with UFP (**Fig E13** in the Online Repository). Of note, treatment with the anti-Notch4 occasionally suppressed residual Th cell cytokine production (e.g. IL-4 production) beyond what could be accounted for by Jag1 activation, suggesting an additional contribution by other Notch ligands acting via Notch4 in supporting those Th cell responses.

The specificity and efficacy of the anti-Notch4 mAb in blocking Notch signaling in allergen-specific T cells was further ascertained in *in vitro* co-cultures of OVA₃₂₃₋₃₃₉ and UFP-treated AM with *Il4ra*^{R576}CD4⁺DO11.10⁺Rag2^{-/-} T cells, in which treatment with anti-Notch4 mAb blocked the transcriptional upregulation of the Notch target genes *Hes1*, *Hey1* and *Nrarp* (**Fig E14** in the Online Repository). Overall, these findings implicated Notch4 as a key Notch receptor through which Jag1 mediates the inflammatory responses to UFP by promoting Th cell differentiation.

Notch4 inhibition suppresses the exacerbation of allergic airway inflammation by UFP. Given the efficacy of the neutralizing anti-Notch4 mAb in reversing the augmented *in vitro* differentiation of allergen-specific Th cells induced by UFP treatment of allergen peptide-presenting AM, we examined the impact of inhibiting Notch4 on the exacerbation of the allergic airway inflammatory response induced by UFP. Accordingly, *Il4ra*^{R576} mice sensitized and challenged with OVA alone or together with UFP, were treated with either an anti-Notch4 or an isotype control mAb during the challenge phase then analyzed for the various parameters of the airway allergic inflammatory response. *In vivo*, treatment with the anti-Notch4 mAb had little or no effect on OVA-induced allergic airway inflammation in terms of tissue inflammation, airway hyper-responsiveness, BAL fluid eosinophilia, serum total and OVA-specific IgE response, and airway Th2 and Th17 cell responses. In contrast, it completely inhibited the potentiation of the aforementioned parameters induced by UFP, thus implicating Notch4 in mediating the potentiating effects of UFP on allergic airway inflammation (**Fig 7, A-G**).

DISCUSSION

Our previous studies have demonstrated that traffic-related PM, including UFP and FP, promotes allergic airway inflammation by inducing Jag1 expression on APCs in an AhR-dependent manner, which in turn activates Notch signaling to augment Th cytokine expression by allergen-specific T cells¹⁵. In this study, we have identified AM as the key target of PM by virtue of their avid uptake of nano and micro particles and their super-induction of Jag1 expression upon PM uptake as compared to other lung APCs. We have also identified Notch4 on T cells as a key mediator of the Jag1-dependent upregulation by UFP-treated AM of allergen-specific Th cell differentiation and iTreg cell destabilization. Notch4 inhibition by means of a neutralizing anti-Notch4 mAb completely abrogated the upregulation by UFP of allergic airway inflammation. These studies thus established cellular elements, including AM and allergen-specific CD4⁺ Th and Treg cells, and molecular effectors, including Jag1 and Notch4, involved in mediating the pro-inflammatory effects of the PM-activated AhR-Jag1-Notch circuit in allergic airway inflammation.

AM have been implicated in the homeostatic maintenance of tolerance in the airways by virtue of their down regulation of the antigen presenting capacity of DC⁵⁰, as well as their promotion of iTreg cell differentiation²³. AM are also less effective in presenting antigens as compared to DC, a defect that could be overcome by the provision of an accessory signal such as co-stimulation of T cells with CD28 or IL-2^{51, 52}. Upregulation of Jag1 expression in AM by PM-mediated activation of AhR may enable efficient antigen presentation with Jag1-Notch acting as a co-receptor pair that amplifies Th cell cytokine production⁵³. Our results clearly demonstrate a necessary and sufficient role

for Jag1-sufficient AM to rescue the augmentation by UFP of allergic airway inflammation in mice lacking Jag1 in their myeloid lineages. Under inflammatory conditions, increased uptake of nanoparticles by IM was noted, possibly reflecting in part the increased abundance of the latter cells in inflamed lung tissues and/or their heightened avidity for these particles. Nevertheless, reconstitution of *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice with either IM or DC failed to rescue the inflammatory responses to UFP, indicative of the requisite role of Jag1-sufficient AM in this process.

While deletion of Jag1 on AM reversed UFP-induced augmentation of allergic airway inflammation, it also attenuated a few parameters of allergen-induced airway inflammation in the absence of UFP, such as the mobilization of CD4⁺ T cell in lung tissues (**Fig 4 and 5**). These findings argue that in the absence of UFP treatment residual Jag1 expression on AM may contribute to allergen-induced airway inflammation, and that UFP acts to greatly amplify this process.

A surprising finding in our studies was the identification of Notch4 as a key Notch receptor through which UFP-mediated their effects in upregulating allergic airway inflammation. Notch4 inhibition provided effective and uniform suppression of UFP and AM-dependent *in vitro* differentiation of allergen-specific T cells into different Th cell subsets. In contrast, inhibition of other Notch receptors, including, including Notch1 and Notch2, provided selective and/or partial inhibition of Th cell cytokine expression. Notch4 inhibition also suppressed the exacerbation by UFP of allergic airway inflammation in mice. The *NOTCH4* locus has previously been associated with severe asthma⁵⁴, suggesting that this pathway may modulate disease severity, especially in as it relates to environmental exposures such as to UFP.

The mechanisms by which Notch4 may selectively contribute to allergic airway inflammation are currently unclear. Jag1 expressed on AM may preferentially interact with Notch4 as compared to other Notch receptors. Alternatively or in parallel, Notch4 may act to differentially amplify the production of Th cell cytokines, or possibly instruct their specific production, as compared to other Notch receptors by means of Notch canonical and non-canonical signaling mechanisms^{53, 55}. Notch4 signaling also destabilized differentiating of iTreg cells, leading to their production of Th cell cytokines. Such an iTreg cell phenotype is associated with decreased suppressive function and lineage instability, potentially leading to the terminal differentiation of Treg cells into Th cell lineages^{30, 56}. Our previous studies have documented an inhibitory function of Notch signaling in Treg cells in controlling their regulatory functions⁴⁸. The differential contribution of Jag1-Notch4 signaling in allergen-specific Th versus iTreg cells in mediating disease exacerbation by UFP remains to be determined. Also unclear is whether Notch4 signaling in Treg cells plays a unique, non-redundant role in regulating their function as compared to other Notch receptors. Distinct, dedicated functions of different Notch receptors in Th and Treg cell populations in allergic airway inflammation may offer opportunities for targeted therapeutic interventions. Finally, and in addition to targeting T cells, a neutralizing Notch4 mAb may act *in vivo* to modulate additional cellular elements, such as the vascular endothelium, involved in mobilizing the airway inflammatory response^{57, 58}. Future studies will be required to delineate the respective contributions of these mechanisms to UFP-promoted allergic airway inflammation.

ACKNOWLEDGEMENTS

464 This work was supported by National Institutes of Health grants 2R01AI065617 and
465 R01AI115699 (to T.A.C.).

466

FIGURE LEGENDS

Fig 1. AM differentially uptake nanoparticles and highly express Jag1 in response to UFP. **A** and **B**, Flow cytometric analysis of the uptake of fluorescent nanoparticles by different lung cell populations in mice subjected to OVA+UFP-induced allergic airway inflammation. **C**, Bar graph presentation of the distribution of nanoparticles among lung macrophages (AM and IM), dendritic cells (DC) and neutrophils (Neu). **D** and **E**, Relative fold changes in *Jag1* transcripts, quantitated by RT-PCR (Fig 1, *D*), and flow cytometric analysis of Jag1 expression (Fig 1, *E*), in lung APCs purified from either *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Ahr*^{Δ/Δ} mice and treated with PBS or UFP (10 μg/ml). **F** and **G**, Relative fold changes in *Jag1* transcripts (Fig 1, *D*), and Jag1 expression (Fig 1, *E*), in lung APCs purified from either *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice and treated with PBS or UFP, as described for Fig 1, *D* and *E*. Results are representative of 2 independent experiments. N=3 mice/group. *p<.05; **p<.01; ***p<.001, ****p<.0001 by one-way ANOVA with post-test analysis (panels *C*, *D* and *F*) or Student's unpaired two-tailed *t* test (panel *F*, CD11c⁺ DC group comparison).

Fig 2. AM support UFP-dependent upregulation of Th cell cytokine production by allergen-specific CD4⁺ T cells in a Jag1-dependent manner. **A**, Representative flow cytometric analysis of IL-4, IL-13, IL-17 and IFN-γ cytokine production by naive *Il4ra*^{R576}CD4⁺DO11.10⁺Rag2^{-/-} T cells co-cultured with FACS-purified AM isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice pulsed with OVA₃₂₃₋₃₃₉ peptide in the presence of

UFP (10 μ g/mL). Cytokine expression was analyzed in gated CD4⁺Foxp3⁻ T cell. **B**, Frequencies of CD4⁺Foxp3⁻ T cells expressing the respective cytokine upon co-culture with AM that have been either sham treated (PBS) or pulsed with OVA₃₂₃₋₃₃₉ peptide, alone or in the presence of UFP. Results are representative of 3 independent experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001, two-way ANOVA with post-test analysis.

Fig 3. UFP skews AM-dependent iTreg cell differentiation towards Th2/17 cell like phenotypes in Jag1-dependent manner. **A**, Representative flow cytometric analysis of the frequencies of CD4⁺Foxp3⁺ iTreg cells and their expression of IL-4, IL-13, IL-17 and IFN- γ upon co-culture of naive *Il4ra*^{R576}CD4⁺DO11.10⁺Rag2^{-/-} T cells with FACS-purified AM isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1* Δ/Δ mice pulsed with OVA₃₂₃₋₃₃₉ peptide in the presence of UFP. **B**, Frequencies of Foxp3⁺ iTreg cells and subgroups thereof expressing the respective cytokine that have been either sham treated (PBS) or pulsed with OVA₃₂₃₋₃₃₉ peptide, alone or in the presence of UFP. Results are representative of 3 independent experiments. **P < .01, ***P < .001, and ****P < .0001, two-way ANOVA with post-test analysis.

Fig 4. Myeloid lineage-specific deletion of *Jag1* confers protection against UFP-induced exacerbation of allergic airway inflammation. **A**, Representative PAS-stained sections of lung isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1* Δ/Δ mice in PBS, OVA or OVA+UFP

groups (200X magnification). **B**, Inflammation scores in the lung tissues isolated from the mouse groups described in Fig 4, A. **C-G** Airway hyper-responsiveness in response to methacholine (Fig 4, C), absolute numbers of eosinophils (Fig 4, D) and T cells (Fig 4, E) in the BAL fluids, total (Fig 4, F) and OVA-specific (Fig 4, G) levels in the serum of the mouse groups described in Fig 4, A. **H-K**, Absolute numbers of lung Foxp3⁺CD4⁺T cells secreting IL-4 (Fig 4, H), IL13 (Fig 4, I), IL-17 (Fig 3, J) and IFN- γ (Fig 4, K) in the mouse groups described in Fig 4, A. **L-O**, Absolute numbers of lung Foxp3⁺CD4⁺Treg cells secreting IL-4 (Fig 4, L), IL13 (Fig 4, M), IL-17 (Fig 4, N) and IFN- γ (Fig 3, O) in the mouse groups described in panel Fig 4, A. Results are representative of 2 independent experiments. N=5 mice/group. *p<0.05, **<0.01, ***<0.001, ****<0.0001 by two-way ANOVA with post test analysis.

Fig 5. Jag1-sufficient AM rescue UFP-mediated allergic airway inflammation in *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1* Δ/Δ mice. **A**, Representative PAS-stained sections of lung tissues of *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1* Δ/Δ mice supplemented intra-tracheally with AM isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1* Δ/Δ mice that were either sham treated (PBS) or loaded with OVA323-339 peptide (OVA) alone or together with UFP (OVA+UFP). **B**, Inflammation scores of lung tissues of mice described in Fig 5, A. **C-G**, Airway hyper-responsiveness (Fig 5, C), numbers of eosinophils (Fig 5, D) and T cells (Fig 5, E) in the BAL fluids, total (Fig 5, F) and OVA-specific (Fig 5, G) levels in the sera of mice described in Fig 5, A. **H-K**, Numbers of lung Foxp3⁺CD4⁺T cells secreting IL-4 (Fig 5, H), IL13 (Fig 5, I), IL-17 (Fig 5, J) and IFN- γ (Fig 5, K) in the BAL fluids of mice described in

Fig 5, A. **L-O**, Numbers of lung Foxp3⁺CD4⁺Treg cells secreting IL-4 (Fig 5, L), IL13 (Fig 5, M), IL-17 (Fig 5, N) and IFN- γ (Fig 5 O) in the BAL fluids of mice described in Fig 5, A. Results are representative of 3 independent experiments. N=7-12 mice/group. *p<0.05, **<0.01, ***<0.001, ****<0.0001 by two-way ANOVA with Bonferroni post test analysis. n.s.: not significant.

Fig 6. AM supports UFP-dependent upregulation of Th cell cytokine production by allergen-specific CD4⁺ T cells in a Notch4-dependent manner. **A**, Representative flow cytometric analysis of IL-4, IL-13 and IL-17 cytokine production by naive *Il4ra*^{R576}CD4⁺DO11.10⁺Rag2^{-/-} T cells co-cultured with FACS-purified AM isolated from *l4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1* ^{Δ/Δ} mice that have been pulsed with OVA₃₂₃₋₃₃₉ peptide in the presence of UFP (10 μ g/mL). Co-cultures were treated with either isotype control (Iso) Ab or an anti-Notch4 mAb, as indicated, and cytokine analysis was carried out on gated CD4⁺Foxp3⁻ T cell. **B**, Frequencies of T cells expressing the respective cytokine upon co-culture with AM that have been either sham treated (PBS) or pulsed with OVA₃₂₃₋₃₃₉ peptide alone or in combination with UFP (10 μ g/mL). Anti-Notch4 mAb or isotype control Ab were added as indicated. Results are representative of 3 independent experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001, two-way ANOVA with post-test analysis.

Fig 7. UFP enhances allergic airway inflammation in a Notch4-dependent manner. **A**, Representative PAS staining of lung tissues isolated from *Il4ra*^{R576} mice sensitized and challenged with OVA alone, or together with UFP, in the presence of either isotype

control (Iso) Ab or an anti-Notch4 mAb. **B**, Inflammation scores in lung tissues of the mouse groups described in Fig 7, A. **C-H** Airway hyper-responsiveness in response to methacholine (Fig 7, C), absolute numbers of eosinophils (Fig 7, D), T cells (Fig 7, E) and neutrophils (Fig 7, F) in the BAL fluids, total (Fig 7, G) and OVA-specific (Fig 7, H) levels in the serum of the mouse groups described in Fig 7, A. **I-L**, Absolute numbers of lung Foxp3⁺CD4⁺T cells secreting IL-4 (Fig 7, I), IL13 (Fig 7, J), IL-17 (Fig 7, K) and IFN- γ (Fig 7, L) in the mouse groups described in Fig 7, A. **M-P**, Absolute numbers of lung Foxp3⁺CD4⁺Treg cells secreting IL-4 (Fig 7, L), IL13 (Fig 7, M), IL-17 (Fig 7, N) and IFN- γ (Fig 7, O) in the mouse groups described in panel Fig 7, A. Results are representative of 2 independent experiments. N=5 mice/group. *p<0.05, **<0.01, ***<0.001, ****<0.0001 by two-way ANOVA with post test analysis.

REFERENCES

1. Brandt EB, Myers JM, Ryan PH, Hershey GK. Air pollution and allergic diseases. *Curr Opin Pediatr* 2015; 27:724-35.
2. Bowatte G, Lodge C, Lowe AJ, Erbas B, Perret J, Abramson MJ, et al. The influence of childhood traffic-related air pollution exposure on asthma, allergy and sensitization: a systematic review and a meta-analysis of birth cohort studies. *Allergy* 2015; 70:245-56.
3. Gehring U, Wijga AH, Hoek G, Bellander T, Berdel D, Bruske I, et al. Exposure to air pollution and development of asthma and rhinoconjunctivitis throughout childhood and adolescence: a population-based birth cohort study. *Lancet Respir Med* 2015; 3:933-42.
4. Adar SD, Filigrana PA, Clements N, Peel JL. Ambient Coarse Particulate Matter and Human Health: A Systematic Review and Meta-Analysis. *Curr Environ Health Rep* 2014; 1:258-74.
5. Khreis H, Kelly C, Tate J, Parslow R, Lucas K, Nieuwenhuijsen M. Exposure to traffic-related air pollution and risk of development of childhood asthma: A systematic review and meta-analysis. *Environ Int* 2017; 100:1-31.
6. Brunst KJ, Ryan PH, Brokamp C, Bernstein D, Reponen T, Lockey J, et al. Timing and Duration of Traffic-related Air Pollution Exposure and the Risk for Childhood Wheeze and Asthma. *Am J Respir Crit Care Med* 2015; 192:421-7.
7. Dockery DW, Pope CA, 3rd. Acute respiratory effects of particulate air pollution. *Annu Rev Public Health* 1994; 15:107-32.
8. Brunekreef B, Holgate ST. Air pollution and health. *Lancet* 2002; 360:1233-42.

9. Saxon A, Diaz-Sanchez D. Air pollution and allergy: you are what you breathe. *Nat Immunol* 2005; 6:223-6.
10. Nel A. Atmosphere. Air pollution-related illness: effects of particles. *Science* 2005; 308:804-6.
11. Diaz-Sanchez D, Dotson AR, Takenaka H, Saxon A. Diesel exhaust particles induce local IgE production in vivo and alter the pattern of IgE messenger RNA isoforms. *J Clin Invest* 1994; 94:1417-25.
12. Diaz-Sanchez D, Tsien A, Fleming J, Saxon A. Combined diesel exhaust particulate and ragweed allergen challenge markedly enhances human in vivo nasal ragweed-specific IgE and skews cytokine production to a T helper cell 2-type pattern. *J Immunol* 1997; 158:2406-13.
13. Li N, Harkema JR, Lewandowski RP, Wang M, Bramble LA, Gookin GR, et al. Ambient ultrafine particles provide a strong adjuvant effect in the secondary immune response: implication for traffic-related asthma flares. *Am J Physiol Lung Cell Mol Physiol* 2010; 299:L374-83.
14. Brandt EB, Kovacic MB, Lee GB, Gibson AM, Acciani TH, Le Cras TD, et al. Diesel exhaust particle induction of IL-17A contributes to severe asthma. *J Allergy Clin Immunol* 2013; 132:1194-204 e2.
15. Xia M, Viera-Hutchins L, Garcia-Lloret M, Noval Rivas M, Wise P, McGhee SA, et al. Vehicular exhaust particles promote allergic airway inflammation through an aryl hydrocarbon receptor-notch signaling cascade. *J Allergy Clin Immunol* 2015.

- 608 16. Oberdorster G. Pulmonary effects of inhaled ultrafine particles. *Int Arch Occup Environ*
609 *Health* 2001; 74:1-8.
- 610 17. Brandt EB, Biagini Myers JM, Acciani TH, Ryan PH, Sivaprasad U, Ruff B, et al.
611 Exposure to allergen and diesel exhaust particles potentiates secondary allergen-
612 specific memory responses, promoting asthma susceptibility. *J Allergy Clin Immunol*
613 2015; 136:295-303 e7.
- 614 18. Hiraiwa K, van Eeden SF. Contribution of lung macrophages to the inflammatory
615 responses induced by exposure to air pollutants. *Mediators Inflamm* 2013; 2013:619523.
- 616 19. Hardy CL, Lemasurier JS, Mohamud R, Yao J, Xiang SD, Rolland JM, et al. Differential
617 uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete
618 immunological imprints. *J Immunol* 2013; 191:5278-90.
- 619 20. Blank F, Stumbles PA, Seydoux E, Holt PG, Fink A, Rothen-Rutishauser B, et al. Size-
620 dependent uptake of particles by pulmonary antigen-presenting cell populations and
621 trafficking to regional lymph nodes. *Am J Respir Cell Mol Biol* 2013; 49:67-77.
- 622 21. Garbi N, Lambrecht BN. Location, function, and ontogeny of pulmonary macrophages
623 during the steady state. *Pflugers Arch* 2017; 469:561-72.
- 624 22. Kopf M, Schneider C, Nobs SP. The development and function of lung-resident
625 macrophages and dendritic cells. *Nat Immunol* 2015; 16:36-44.
- 626 23. Coleman MM, Ruane D, Moran B, Dunne PJ, Keane J, Mills KH. Alveolar macrophages
627 contribute to respiratory tolerance by inducing FoxP3 expression in naive T cells. *Am J*
628 *Respir Cell Mol Biol* 2013; 48:773-80.


24. Soroosh P, Doherty TA, Duan W, Mehta AK, Choi H, Adams YF, et al. Lung-resident tissue macrophages generate Foxp3⁺ regulatory T cells and promote airway tolerance. *J Exp Med* 2013; 210:775-88.
25. Duan W, So T, Croft M. Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3⁺ T regulatory cells. *J Immunol* 2008; 181:8650-9.
26. Moon KA, Kim SY, Kim TB, Yun ES, Park CS, Cho YS, et al. Allergen-induced CD11b⁺ CD11c(int) CCR3⁺ macrophages in the lung promote eosinophilic airway inflammation in a mouse asthma model. *Int Immunol* 2007; 19:1371-81.
27. Miyata R, van Eeden SF. The innate and adaptive immune response induced by alveolar macrophages exposed to ambient particulate matter. *Toxicol Appl Pharmacol* 2011; 257:209-26.
28. de Haar C, Kool M, Hassing I, Bol M, Lambrecht BN, Pieters R. Lung dendritic cells are stimulated by ultrafine particles and play a key role in particle adjuvant activity. *J Allergy Clin Immunol* 2008; 121:1246-54.
29. Tachdjian R, Mathias C, Al Khatib S, Bryce PJ, Kim HS, Blaeser F, et al. Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma. *J Exp Med* 2009; 206:2191-204.
30. Massoud AH, Charbonnier LM, Lopez D, Pellegrini M, Phipatanakul W, Chatila TA. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. *Nat Med* 2016; 22:1013-22.


- 650 31. Walisser JA, Glover E, Pande K, Liss AL, Bradfield CA. Aryl hydrocarbon receptor-
651 dependent liver development and hepatotoxicity are mediated by different cell types.
652 Proc Natl Acad Sci U S A 2005; 102:17858-63.
- 653 32. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in
654 macrophages and granulocytes using LysMcre mice. Transgenic Res 1999; 8:265-77.
- 655 33. Mancini SJ, Mantei N, Dumortier A, Suter U, MacDonald HR, Radtke F. Jagged1-
656 dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and
657 differentiation. Blood 2005; 105:2340-2.
- 658 34. Shirmohammadi F, Hasheminassab S, Saffari A, Schauer JJ, Delfino RJ, Sioutas C.
659 Fine and ultrafine particulate organic carbon in the Los Angeles basin: Trends in sources
660 and composition. Sci Total Environ 2016; 541:1083-96.
- 661 35. Murata A, Yoshino M, Hikosaka M, Okuyama K, Zhou L, Sakano S, et al. An
662 evolutionary-conserved function of mammalian notch family members as cell adhesion
663 molecules. PLoS One 2014; 9:e108535.
- 664 36. Blaeser F, Bryce PJ, Ho N, Raman V, Dedeoglu F, Donaldson DD, et al. Targeted
665 inactivation of the IL-4 receptor alpha chain I4R motif promotes allergic airway
666 inflammation. J Exp Med 2003; 198:1189-200.
- 667 37. Ford JG, Rennick D, Donaldson DD, Venkayya R, McArthur C, Hansell E, et al. Il-13 and
668 IFN-gamma: interactions in lung inflammation. J Immunol 2001; 167:1769-77.
- 669 38. McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergen-induced airway remodeling
670 by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. J
671 Immunol 2005; 174:5774-80.


39. Li N, Wang M, Bramble LA, Schmitz DA, Schauer JJ, Sioutas C, et al. The adjuvant effect of ambient particulate matter is closely reflected by the particulate oxidant potential. *Environ Health Perspect* 2009; 117:1116-23.
40. Li N, Georas S, Alexis N, Fritz P, Xia T, Williams MA, et al. A work group report on ultrafine particles (American Academy of Allergy, Asthma & Immunology): Why ambient ultrafine and engineered nanoparticles should receive special attention for possible adverse health outcomes in human subjects. *J Allergy Clin Immunol* 2016; 138:386-96.
41. Whitekus MJ, Li N, Zhang M, Wang M, Horwitz MA, Nelson SK, et al. Thiol antioxidants inhibit the adjuvant effects of aerosolized diesel exhaust particles in a murine model for ovalbumin sensitization. *J Immunol* 2002; 168:2560-7.
42. Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GR, Perlman H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. *Am J Respir Cell Mol Biol* 2013; 49:503-10.
43. Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D, Popovich PG, Partida-Sanchez S, et al. Novel Markers to Delineate Murine M1 and M2 Macrophages. *PLoS One* 2015; 10:e0145342.
44. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol* 2004; 25:677-86.
45. Katakura T, Miyazaki M, Kobayashi M, Herndon DN, Suzuki F. CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. *J Immunol* 2004; 172:1407-13.


- 694 46. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and
 695 function of dendritic cells and their subsets in the steady state and the inflamed setting.
 696 *Annu Rev Immunol* 2013; 31:563-604.
- 697 47. Abram CL, Roberge GL, Hu Y, Lowell CA. Comparative analysis of the efficiency and
 698 specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. *J Immunol*
 699 *Methods* 2014; 408:89-100.
- 700 48. Charbonnier LM, Wang S, Georgiev P, Sefik E, Chatila TA. Control of peripheral
 701 tolerance by regulatory T cell-intrinsic Notch signaling. *Nat Immunol* 2015; 16:1162-73.
- 702 49. Moriyama Y, Sekine C, Koyanagi A, Koyama N, Ogata H, Chiba S, et al. Delta-like 1 is
 703 essential for the maintenance of marginal zone B cells in normal mice but not in
 704 autoimmune mice. *Int Immunol* 2008; 20:763-73.
- 705 50. Holt PG, Oliver J, Bilyk N, McMenamin C, McMenamin PG, Kraal G, et al.
 706 Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in
 707 vivo by resident alveolar macrophages. *J Exp Med* 1993; 177:397-407.
- 708 51. Blumenthal RL, Campbell DE, Hwang P, DeKruyff RH, Frankel LR, Umetsu DT. Human
 709 alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells. *J*
 710 *Allergy Clin Immunol* 2001; 107:258-64.
- 711 52. Chelen CJ, Fang Y, Freeman GJ, Secrist H, Marshall JD, Hwang PT, et al. Human
 712 alveolar macrophages present antigen ineffectively due to defective expression of B7
 713 costimulatory cell surface molecules. *J Clin Invest* 1995; 95:1415-21.


53. Bailis W, Yashiro-Ohtani Y, Fang TC, Hatton RD, Weaver CT, Artis D, et al. Notch simultaneously orchestrates multiple helper T cell programs independently of cytokine signals. *Immunity* 2013; 39:148-59.
54. Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Doi S, et al. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. *Nat Genet* 2011; 43:893-6.
55. Tindemans I, Peeters MJW, Hendriks RW. Notch Signaling in T Helper Cell Subsets: Instructor or Unbiased Amplifier? *Front Immunol* 2017; 8:419.
56. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3⁺ T cells into TH17 cells in autoimmune arthritis. *Nat Med* 2014; 20:62-8.
57. Uyttendaele H, Closson V, Wu G, Roux F, Weinmaster G, Kitajewski J. Notch4 and Jagged-1 induce microvessel differentiation of rat brain endothelial cells. *Microvasc Res* 2000; 60:91-103.
58. Miniati D, Jelin EB, Ng J, Wu J, Carlson TR, Wu X, et al. Constitutively active endothelial Notch4 causes lung arteriovenous shunts in mice. *Am J Physiol Lung Cell Mol Physiol* 2010; 298:L169-77.














**A Jagged1-Notch4 Molecular Switch Mediates Airway Inflammation by Ultrafine
Particles**

Mingcan Xia, PhD^a, Hani Harb PhD^a, Arian Saffari, PhD^b, Constantinos Sioutas, Sc.D.^b
and Talal A. Chatila, MD, MSc^a

^aDivision of Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard
Medical School, Boston, MA 02115; ^bDepartment of Civil and Environmental
Engineering, University of Southern California, Los Angeles, California, 90089

Corresponding Author: Talal A. Chatila, Division of Immunology, Department of
Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115
(talal.chatila@childrens.harvard.edu).

SUPPLEMENTARY METHODS

Reagents The aryl hydrocarbon receptor (AhR) ligand 6-Formylindolo (3,2-b) carbazole (FICZ) was purchased from Santa Cruz Biotechnology. Lyophilized dust mites (*D. Pteronyssinus*) whole body extract was obtained from Greer (Lenoir, NC). Fluoresbrite® yellow green (YG) microspheres (1.00 µm diameter) and nanobeads (0.05 µm diameter) were bought from Polysciences (Warrington, PA). For some experiments, mice were intranasally (*i.n*) administered Fluoresbrite® yellow green (YG) microspheres or nanobeads alone (10 µg/100 µl PBS/instillation) or the mixture of microspheres or nanobeads with UFP at 1:1 ratio (10 µg microspheres or nanobeads + 10 µg UFP in 100 µl PBS instillation).

Real time PCR analysis. Lung AM, IM and DC were purified by cell sorting from the respective donor mouse strain. They were further treated with either PBS(sham) or 10µg/ml UFP for 12 hours. Total RNA was collected for target gene analysis. *Il4ra*^{R576}*Foxp3*^{EGFP} mice, described in earlier publications^{1,2}, were used for analysis of Notch receptor expression on T cells. Briefly, *Il4ra*^{R576}*Foxp3*^{EGFP} mice were sensitized and boosted with 100µg OVA in 100µl PBS by *i.p* injection. Starting on day 29, OVA-sensitized mice were challenged with aerosolized OVA at 1%, for 30 minutes daily for 3 days. Two hours before each OVA aerosol exposure, subgroups of mice were given intranasally (*i.n.*) either PBS or UFP at 10 µg/100µl PBS/instillation. After challenge, lung tissue were collected and digested with 1mg/ml Collagenase IV for 2 hours. *CD3*⁺*CD4*⁺*Foxp3*^{EGFP+} and *CD3*⁺*CD4*⁺*Foxp3*^{EGFP-} cells from lung or spleen (control) were purified by cell sorting based on EGFP expression. cDNA was reverse transcribed from 2 µg of RNA/sample and used in real-time PCR assays that employed Taqman

(Applied Biosystems). The comparative Ct (threshold cycle) method normalized to GAPDH was used to analyze relative changes in gene expression. The fold-change was calculated as $2^{-\Delta\Delta Ct}$ for $\Delta\Delta Ct$ values (indicating a fold change).

Antibodies, Flow cytometry and intracellular staining. Single-cell suspensions were stained with the indicated antibodies (Ab) and analyzed on LSRIIFortessa cytometer (Becton Dickinson). Cytokine expression in CD4⁺ T cells was determined by stimulating cells with PMA (20 ng/ml) plus ionomycin (1 µg/ml) for 4 hours in the presence of Golgi-plug (BD Biosciences) followed by intracellular staining for the respective cytokine using the eBioscience Fixation/Permeabilization buffer following the manufacturer's instructions. Fluorescence-conjugated mAbs used were obtained from BD Biosciences, Biolegend and eBioscience. Anti-CD3-FITC, PEcy7, PerCPCy5.5 (145 2C11), anti-CD4-AF700 (GK1.5), anti-CD8-PerCPCy5.5 (53-6.7), anti-B220-APC (RA3-6B2), anti-F4/80-Pacific Blue (BM8), anti-CD11b-PerCPCy5.5 (M1/70), anti-MHC II I-Ad (39-10-8), anti-Notch2-PE (HMN2-35)³, anti-Notch4-Alexafluor647 (HMN4-14)³ anti-CD45-AF700 (30-F11) and Annexin V apoptosis detection kit were purchased from Biolegend. Anti-CD4 eFluor 450 (GK1.5), anti-CD19-FITC (6D5), anti-Gr-1-PerCPCy5.5 (RB6-8C5), anti-IL4-PE-CF594 (11B11, BD), anti-IL13-PE(eBio13A), anti-IL17-PEcy7 (eBio17B7), anti-IFN-γ-APC (XMG1.2), anti-Jagged-1-PE (HMJ1-29) anti-Notch1-APC (22E5), anti-Notch3-APC (HMN3-133) and anti-CD11c-PEcy7 (N418) were obtained from eBioscience. Anti-Siglec-F-PE (E50-2440) was purchased from BD Bioscience.

For Notch neutralization experiments, Mouse IgG2b Anti-Notch1 mAb (A6)⁴, and Rabbit polyclonal anti-Notch2 (#PA5-47091) and goat polyclonal anti-Notch3 (#PA5-47120)

Ab were purchased from ThermoFisher . Armenian hamster anti-mouse Notch4 IgG mAb and control Armenian hamster IgG polyclonal Ab were purchased from Bio X cell ³.

IgE and Th cytokine ELISAs. Total and OVA-specific IgE concentrations were measured by using sandwich ELISAs as previously described⁵. Culture supernatants of PBS and UFP-treated AM were collected at 48 hr following the incubation of cell-sorted AM with UFP at 10 µg/ml. They were assayed for IL-6, IL-10, IL-12 p40, TNFα and CCL17 by ELISA using detection kits purchased from eBioscience (IL-6, IL-10 and TNFα), Biolegend (IL-12 p40) and R&D (CCL17).

Measurement of airway hyper-responsiveness. Airway resistance was measured 24 h after the last day of OVA or OVA/UFP challenge. The mice were anesthetized and instrumented for the measurement of pulmonary mechanics (BUXCO Electronics) as detailed ². Baseline lung resistance (RL) and responses to aerosolized saline (0.9% NaCl) were measured first, followed by responses to increasing doses (0.32 to 10 mg/ml) of aerosolized acetyl-β-methylcholine chloride (methacholine; Sigma-Aldrich). The three highest values of RL obtained after each dose of methacholine were averaged to obtain the final values for each dose.

UFP Sampling Methodology. Ultrafine particles were collected at the particle instrumentation unit (PIU) of the University of Southern California, using a high volume ultrafine sampler operating at volumetric flow rate of about 400 liters per minute, as described in Saffari et al ⁶. This sampling location is in the vicinity (i.e. about 150 meters downwind) of a major Los Angeles freeway, thus primarily impacted by the vehicular emissions. To determine mass concentrations, as well as concentration of chemical species, UFPs were collected on pre-weighted 8" x 11" Zeflour filter media (supported

PTFE, Pall Life Sciences). After the collection, filters were equilibrated overnight and post-weighted under controlled laboratory conditions. Water soluble elemental content was quantified by extracting a portion of the filters in ultrapure Milli-Q water (by vortexing and sonication) and measurements using a high-resolution sector field inductively coupled plasma mass spectrometry (SF-ICP-MS, Thermo Finnigan Element 2) ⁷. OC was also quantified using a Shimadzu VSH total organic carbon (TOC) analyzer (Shimadzu Inc., Kyoto, Japan) ⁸.

The chemical composition of the UFP used in the experiments is shown in **Table E1** below. Organic Carbon (OC) represents a mixture of primary traffic emission and bulk oxygenated organic compounds, the abundance of which is an indicator of the extent of SOA formation and accounts for the majority of the UFP mass ⁹. The concentrations of organic carbon and selected trace elements, metals and PAH in the UFP fractions employed in these studies are shown in **Table E1**

SUPPLEMENTAL FIGURE LEGENDS

Fig E1. Disposition of fluorescent nanobeads (“Fluoresbrite YG”) in different lung cell subpopulations in mice subjected to sham (PBS), OVA or OVA+UFP-induced allergic airway inflammation. Mice were sensitized with OVA then challenged with PBS (sham treatment), OVA or OVA +UFP. Fluorescent nanobeads were introduced by intranasal instillation in all challenge groups. **A** and **B**, Flow cytometric analysis of the uptake of fluorescent nanoparticles by CD45⁺ lung cell populations (Fig E1, A) and in lung macrophage populations segregated by the markers F4/80 and CD11c (Fig E1, A) followed by CD11b and CD11c (Fig E1, B), in mice subjected to allergic airway inflammation. **C-G**, Distribution of nanobeads in CD45⁺F4/80⁻ cell fraction, sequentially segregated by the indicated markers and respective gates. Results are representative of 2 independent experiments. N=3 mice/group/experiment.

Fig E2. Fluoresbrite YG nanobeads do not induce Jag1 expression in AM or influence allergic airway inflammation in mice. A, Flow cytometric analysis of Jag1 expression in cell-sorted AM cultured *in vitro* for 24 hr and treated with either PBS (sham treatment), Fluoresbrite YG nanobeads or UFP (at 10 µg/ml, respectively). **B-D**, Disposition and effect of fluorescent nanobeads “Fluoresbrite YG” in the OVA model of allergic airway inflammation. Mice were sensitized with OVA then challenged with PBS (sham treatment), or OVA. Fluoresbrite YG nanobeads were introduced by intranasal instillation in a separate OVA-sensitized and challenged group. **B**, Flow cytometric analysis of the uptake of Fluoresbrite YG nanobeads by CD45⁺ lung cell populations and in lung macrophage populations segregated by the markers F4/80 and CD11c

(followed by CD11b and CD11c, in mice subjected to allergic airway inflammation. **C, D**, Airway hyper-responsiveness (RI) and lung eosinophil and lymphocyte counts in the respective mouse groups. N=5 mice/group.

Fig E3. Characterization of fluorescent nanoparticles-uptaking lung macrophages from mice subjected to OVA+UFP-induced allergic airway inflammation. **A and B**, CD45⁺F4/80⁺CD11b^{Int}CD11c^{Hi} AM cells (Fig E2, A) and CD45⁺F4/80⁺CD11b^{Hi}CD11c^{Int} IM cells (Fig E2, B) were stained for the markers CD64, CD38, Egr2 and MHC class II I-A^d, as indicated. Results are representative of two independent experiments, N=3/group/experiment. **C**, Production of IL-6, IL-10, IL-12 p40 subunit, TNF α and CCL17 by cell-sorted AM treated *in vitro* for 48 hr with UFP at 10 μ g/ml. N=5 independent cultures/cytokine assay. $p<****<0.0001$ by Student two tailed *t* test.

Fig E4. Disposition of fluorescent microparticles in different lung cell subpopulations in mice following intranasal instillation under otherwise non-inflammatory conditions (no allergic sensitization). **A**, Flow cytometric analysis of the uptake of fluorescent microparticles by CD45⁺ lung cell populations and in lung macrophage populations segregated by the markers F4/80 and CD11c followed by CD11b and CD11c. **A**, Flow cytometric analysis of the uptake of microparticles in the CD45⁺F4/80⁻ cell fraction, sequentially segregated by the indicated markers and respective gates. Results are representative of 2 independent experiments. N=3 mice/group/experiment.

Fig E5. UFP upregulate Jag1 expression in BM-derived macrophages. **A**, Flow cytometric analysis of Jag1 expression in BM-derived macrophages prepared from either *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Ahr1*^{Δ/Δ} mice and treated *in vitro* with either PBS, UFP (10 μg/ml), 6-FICZ (300 nM) or CB (10 μg/ml). **B**, Flow cytometric analysis of Jag1 expression in AM, IM and DC in lungs of *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Ahr1*^{Δ/Δ} mice sensitized with either PBS or OVA and challenged with OVA or OVA+UFP.

Fig E6. AM support UFP-dependent upregulation of Th cell cytokine production by allergen-specific CD4⁺ T cells in a Jag1-dependent manner. **A-D**, Representative flow cytometric analysis of IL-4 (Fig E5, A), IL-13 (Fig E5, B), IL-17 (Fig E5, C) and IFN-γ (Fig E5, D) cytokine production by naive *Il4ra*^{R576}CD4⁺DO11.10⁺Rag2^{-/-} T cells co-cultured with FACS-purified AM isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice either sham-pulsed (PBS) or pulsed with OVA₃₂₃₋₃₃₉ peptide either alone (OVA) or in the presence of UFP (OVA+UFP).

Fig E7. Myeloid lineage-specific deletion of *Jag1* confers protection against the exacerbation by UFP of allergic airway inflammation induced by DM. **A**, Representative Periodic acid–Schiff (PAS)-stained sections of lung isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice in PBS, DM or DM+UFP groups. **B**, Inflammation scores in the lung tissues isolated from the mouse groups described in Fig E6, A. **C-E** Absolute numbers of eosinophils (Fig E6, C) and T cells (Fig E6, D) in the BAL fluids and serum total IgE concentrations (Fig E6, E) in the mouse groups described in Fig E6, A. **F-I**, Absolute numbers of lung Foxp3⁺CD4⁺T cells secreting IL-4 (Fig E6, F), IL13 (Fig E6, G,

IL-17 (Fig E6, *H*) and IFN- γ (Fig E6, *I*) in the mouse groups described in Fig E6, *A*. **J-M**, Absolute numbers of lung Foxp3⁺CD4⁺Treg cells secreting IL-4 (Fig E6, *J*), IL13 (Fig E6, *K*), IL-17 (Fig E6, *L*) and IFN- γ (Fig E6, *M*) in the mouse groups described in panel Fig 3, *A*. Results are representative of 2 independent experiments. N=5 mice/group. **p*<0.05, **<0.01, ***<0.001, ****<0.0001 by two-way ANOVA with post test analysis.

Fig E8. Myeloid lineage-specific deletion of *Ahr* confers protection against UFP-induced exacerbation of allergic airway inflammation. **A**, Representative Periodic acid–Schiff (PAS)-stained sections of lung isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Ahr1*^{Δ/Δ} mice in PBS, OVA or OVA+UFP groups. **B**, Inflammation scores in the lung tissues isolated from the mouse groups described in Fig E7, *A*. **C-F** Absolute numbers of eosinophils (Fig E7, *C*) and T cells (Fig E7, *D*) in the BAL fluids and serum total (Fig E7, *E*) and OVA-specific (Fig E7, *F*) IgE concentrations in the mouse groups described in Fig E7, *A*. **G-J**, Absolute numbers of lung Foxp3⁺CD4⁺T cells secreting IL-4 (Fig E7, *G*), IL13 (Fig E7, *H*), IL-17 (Fig E7, *I*) and IFN- γ (Fig E7, *J*) in the mouse groups described in Fig E7, *A*. **K-N**, Absolute numbers of lung Foxp3⁺CD4⁺Treg cells secreting IL-4 (Fig E7, *K*), IL13 (Fig E7, *L*), IL-17 (Fig E7, *M*) and IFN- γ (Fig E7, *N*) in the mouse groups described in panel Fig E7, *A*. Results are representative of 2 independent experiments. N=5 mice/group. **p*<0.05, **<0.01, ***<0.001, ****<0.0001 by two-way ANOVA with post test analysis.

Fig E9. *CD11c*^{Cre}-mediated deletion of *Jag1* does not protect against the exacerbation by UFP of allergic airway inflammation induced by DM. **A**, Representative Periodic

acid–Schiff (PAS)-stained sections of lung isolated from *Il4ra*^{R576} or *Il4ra*^{R576} *CD11c*^{Cre} *Jag1*^{ΔΔ} mice in PBS, OVA or OVA+UFP groups. **B**, Inflammation scores in the lung tissues isolated from the mouse groups described in Fig E8, A. **C-F** Absolute numbers of eosinophils (Fig E8, C) and T cells (Fig E8, D) in the BAL fluids and serum total and OVA-specific IgE concentrations (Fig E8, E and F) in the mouse groups described in Fig E8, A. Results are representative of 2 independent experiments. N=5 mice/group. *p<0.05, **<0.01, ***<0.001, ****<0.0001 by two-way ANOVA with post test analysis.

Fig E10. Jag1-sufficient IM and DC fail to rescue UFP-mediated allergic airway inflammation in *Il4ra*^{R576} *Lyz2*^{Cre} *Jag1*^{ΔΔ} mice. **A-F**, IM transfer; **G-L**, DC transfer. Airway hyper-responsiveness in response to methacholine (Fig E9, A and G), absolute numbers of eosinophils (Fig E9 B and H), OVA-specific serum IgE antibody concentrations (Fig 5, C and I), and lung tissue CD4⁺ T cells (Fig 5, D and J), absolute numbers of lung CD4⁺Foxp3⁻ T cells secreting IL13 and IL-17 (Fig 5, E and K), Absolute numbers of lung Foxp3⁺CD4⁺Treg cells secreting IL13 and IL-17 (Fig E9, F and L). N=4 mice/group. *p<0.05, **<0.01, ***<0.001, ****<0.0001 by two-way ANOVA with Bonferroni post test analysis.

Fig E11. Flow cytometric analysis of Notch receptor expression on CD4⁺ T cells in allergic airway inflammation. Left panels: Representative flow cytometric analysis of Notch1-4 staining on CD4⁺ T cells in lungs of mice sensitized with PBS (sham) or OVA then challenged with OVA, or sensitized with OVA and challenged with OVA and UFP (OVA+UFP). Right panels: Frequencies of CD4⁺ T cells expressing the respective

Notch receptor. Results are representative of 2 independent experiments; n=4 mice/group. ***P < .001, and ****P < .0001, one-way ANOVA with post-test analysis.

Fig E12. Effect of neutralizing anti-Notch1-4 mAb treatment on the upregulation of Th cell cytokine production by allergen-specific CD4⁺Foxp3⁻ T cells induced by OVA₃₂₃₋₃₃₉ + UFP-treated AM. **A-D**, Bar graph distribution of IL-4 (Fig E9, A), IL-13 (Fig E9, B), IL-17 (Fig E9, C) and IFN-γ (Fig E9, D) cytokine production by naive *Il4ra*^{R576}CD4⁺DO11.10⁺Rag2^{-/-} T cells co-cultured with FACS-purified AM isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice either sham-pulsed (PBS) or pulsed with OVA₃₂₃₋₃₃₉ peptide either alone (OVA) or in the presence of UFP (OVA+UFP), as indicated. Control or anti-Notch Ab were added as indicated. Results represent means + S.E.M of 6 replicates derived from two independent experiments. **<0.01, ***<0.001, ****<0.0001 by one-way ANOVA with post test analysis.

Fig E13. Effect of neutralizing anti-Notch 4 mAb treatment on the upregulation of Th cell cytokine production by allergen-specific CD4⁺Foxp3⁺ Treg cells induced upon co-culture with allergen + UFP-pulsed AM. **A**, Representative flow cytometric analysis of IL-4, IL-13 and IL-17 cytokine production by CD4⁺Foxp3⁺ Treg cells induced upon the co-culture of *Il4ra*^{R576}CD4⁺DO11.10⁺Rag2^{-/-} naïve T cells with FACS-purified AM isolated from *Il4ra*^{R576} or *Il4ra*^{R576}*Lyz2*^{Cre}*Jag1*^{Δ/Δ} mice and pulsed with OVA₃₂₃₋₃₃₉ and UFP (10 μg/mL). Co-cultures were treated with either isotype control Ab (Iso Ab) or an anti-Notch4 mAb, as indicated, and cytokine analysis was carried out on gated CD4⁺Foxp3⁺ T cell. **B**, Frequencies of Treg cells expressing the respective cytokine upon co-culture with AM

that have been either sham treated (PBS) or pulsed with OVA₃₂₃₋₃₃₉ peptide alone or in combination with UFP (10 µg/mL). Anti-Notch4 mAb or isotype control Ab were added as indicated. Results are representative of 3 independent experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001, two-way ANOVA with post-test analysis.

Fig E14. Inhibition of Notch target gene expression in T cells stimulated with allergen+UFP by treatment with neutralizing anti-Notch 4 mAb. DO11.10⁺ T cells were either sham treated (PBS+ control Ab; white bars) or co-cultured with AM pulsed with OVA₃₂₃₋₃₃₉ peptide + UFP in the presence of either control Ab (black bars) or anti-Notch4 mAb (grey bars), then assayed by real time PCR for the expression of transcripts of the respective target gene. **A**, *Hes1* expression. **B**, *Hey1* expression. **C**, *Nrarp* expression N=4 cultures/group. *<0.05, ***<0.001 by one-way ANOVA with post test analysis.

References

1. Xia M, Viera-Hutchins L, Garcia-Lloret M, Noval Rivas M, Wise P, McGhee SA, et al. Vehicular exhaust particles promote allergic airway inflammation through an aryl hydrocarbon receptor-notch signaling cascade. *J Allergy Clin Immunol* 2015.
2. Massoud AH, Charbonnier LM, Lopez D, Pellegrini M, Phipatanakul W, Chatila TA. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. *Nat Med* 2016; 22:1013-22.
3. Moriyama Y, Sekine C, Koyanagi A, Koyama N, Ogata H, Chiba S, et al. Delta-like 1 is essential for the maintenance of marginal zone B cells in normal mice but not in autoimmune mice. *Int Immunol* 2008; 20:763-73.
4. Sakamoto K, Chao WS, Katsube K, Yamaguchi A. Distinct roles of EGF repeats for the Notch signaling system. *Exp Cell Res* 2005; 302:281-91.
5. Noval Rivas M, Burton OT, Wise P, Zhang YQ, Hobson SA, Garcia Lloret M, et al. A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis. *J Allergy Clin Immunol* 2013; 131:201-12.
6. Saffari A, Hasheminassab S, Shafer MM, Schauer JJ, Chatila TA, Sioutas C. Nighttime aqueous-phase secondary organic aerosols in Los Angeles and its implication for fine particulate matter composition and oxidative potential. *Atmospheric Environment* 2016; 133:112-22.
7. Herner JD, Green PG, Kleeman MJ. Measuring the trace elemental composition of size-resolved airborne particles. *Environ Sci Technol* 2006; 40:1925-33.

- 268 8. Stone EA, Hedman CJ, Sheesley RJ, Shafer MM, Schauer JJ. Investigating the
269 chemical nature of humic-like substances (HULIS) in North American
270 atmospheric aerosols by liquid chromatography tandem mass spectrometry.
271 Atmospheric Environment 2009; 43:4205-13.
- 272 9. Fine PM, Sioutas C, Solomon PA. Secondary particulate matter in the United
273 States: insights from the Particulate Matter Supersites Program and related
274 studies. J Air Waste Manag Assoc 2008; 58:234-53.

TABLE E1. Chemical composition of ultrafine PM aqueous suspensions

Species	Concentration in Aqueous Slurry (ng/g PM)
Organic Carbon	572.78
Na	22.97
Mg	7.46
Al	13.04
S	29.78
K	7.86
Ca	25.15
Ti	0.45
Cr	0.29
Mn	0.36
Fe	15.8
Ni	0.42
Cu	1.55
Zn	5.36
Ba	0.99
Pb	0.63
Benzo(b)fluoranthene	3.2 ± 1.7
Benzo(k)fluoranthene	2.6 ± 1.7
Benzo(e)pyrene	2.1 ± 1.7
Benzo(a)pyrene	N.D
Indeno(1,2,3-cd)pyrene	N.D
Benzo(g,h,i)perylene	3.5 ± 1.7
Coronene	8.4 ± 6.5
Sum of PAHs	19.8 ± 7.3

